快速访问
文章信息
参考文献
[1]Vivarelli M, Gibson K, Sinha A, et al. Childhood nephrotic syndrome[J/OL]. Lancet (London, England), 2023, 402(10404): 809-824. DOI: 10.1016/S0140-6736(23)01051-6.
[2]Shalhoub R J. Pathogenesis of lipoid nephrosis: a disorder of T-cell function[J/OL]. Lancet (London, England), 1974, 2(7880): 556-560. DOI: 10.1016/s0140-6736(74)91880-7.
[3]Benz K, Dötsch J, Rascher W, et al. Change of the course of steroid-dependent nephrotic syndrome after rituximab therapy[J/OL]. Pediatric Nephrology (Berlin, Germany), 2004, 19(7): 794-797. DOI: 10.1007/s00467-004-1434-z.
[4]曹雪涛等.医学免疫学 第7版[M].北京：人民卫生出版社,2018:81.
[5]Ling C, Wang X, Chen Z, et al. Altered B-Lymphocyte Homeostasis in Idiopathic Nephrotic Syndrome[J/OL]. Frontiers in Pediatrics, 2019, 7: 377. DOI: 10.3389/fped.2019.00377.
[6]Ling C, Chen Z, Fan J, et al. Decreased Circulating Transitional B-Cell to Memory B-Cell Ratio Is a Risk Factor for Relapse in Children with Steroid-Sensitive Nephrotic Syndrome[J/OL]. Nephron, 2021, 145(2): 107-112. DOI: 10.1159/000511319.
[7]阳海平.调节性B细胞在儿童原发性肾病综合征Th17/Treg免疫失衡中的作用及机制研究[D].重庆医科大学.
[8]Ye Q, Chen A, Lai E Y, et al. Autoimmune Podocytopathies: A Novel Sub-Group of Diseases from Childhood Idiopathic Nephrotic Syndrome[J/OL]. Journal of the American Society of Nephrology: JASN, 2022, 33(3): 653-654. DOI: 10.1681/ASN.2021111469.
[9]Ye Q, Zhang Y, Zhuang J, et al. The important roles and molecular mechanisms of annexin A2 autoantibody in children with nephrotic syndrome[J/OL]. Annals of Translational Medicine, 2021, 9(18): 1452. DOI: 10.21037/atm-21-3988.
[10]Watts A J B, Keller K H, Lerner G, et al. Discovery of Autoantibodies Targeting Nephrin in Minimal Change Disease Supports a Novel Autoimmune Etiology[J/OL]. Journal of the American Society of Nephrology: JASN, 2022, 33(1): 238-252. DOI: 10.1681/ASN.2021060794.
[11]Jamin A, Berthelot L, Couderc A, et al. Autoantibodies against podocytic UCHL1 are associated with idiopathic nephrotic syndrome relapses and induce proteinuria in mice[J/OL]. Journal of Autoimmunity, 2018, 89: 149-161. DOI: 10.1016/j.jaut.2017.12.014.
[12]Tkaczyk M, Czupryniak A, Owczarek D, et al. Markers of endothelial dysfunction in children with idiopathic nephrotic syndrome[J/OL]. American Journal of Nephrology, 2008, 28(2): 197-202. DOI: 10.1159/000110088.
[13]Coward R J M, Foster R R, Patton D, et al. Nephrotic plasma alters slit diaphragm-dependent signaling and translocates nephrin, podocin, and CD2 associated protein in cultured human podocytes[J/OL]. Journal of the American Society of Nephrology, 2005, 16(3): 629-637. DOI: 10.1681/ASN.2004030172.
[14]Roopenian D C, Akilesh S. FcRn: the neonatal Fc receptor comes of age[J/OL]. Nature Reviews. Immunology, 2007, 7(9): 715-725. DOI: 10.1038/nri2155.
[15]Bertelli R, Bonanni A, Di Donato A, et al. Regulatory T cells and minimal change nephropathy: in the midst of a complex network[J/OL]. Clinical and Experimental Immunology, 2016, 183(2): 166-174. DOI: 10.1111/cei.12675.
[16]Chebotareva N, Bobkova I, Lysenko L. T regulatory cells in renal tissue of patients with nephrotic syndrome[J/OL]. Pediatrics International: Official Journal of the Japan Pediatric Society, 2020, 62(7): 884-885. DOI: 10.1111/ped.14294.
[17]Tunçay S C, Hakverdi G, Şenol Ö, et al. Regulatory T-cell Changes in Patients with Steroid-Resistant Nephrotic Syndrome after Rituximab Therapy[J/OL]. Saudi Journal of Kidney Diseases and Transplantation: An Official Publication of the Saudi Center for Organ Transplantation, Saudi Arabia, 2021, 32(4): 1028-1033. DOI: 10.4103/1319-2442.338276.
[18]Kim A H, Chung J J, Akilesh S, et al. B cell-derived IL-4 acts on podocytes to induce proteinuria and foot process effacement[J/OL]. JCI insight, 2017, 2(21): e81836, 81836. DOI: 10.1172/jci.insight.81836.
[19]Srivastava T, Joshi T, Heruth D P, et al. A mouse model of prenatal exposure to Interleukin-6 to study the developmental origin of health and disease[J/OL]. Scientific reports, 2021, 11(1): 13260. DOI: 10.1038/s41598-021-92751-6.
[20]Mackay F, Browning J L. BAFF: a fundamental survival factor for B cells[J/OL]. Nature Reviews. Immunology, 2002, 2(7): 465-475. DOI: 10.1038/nri844.
[21]Oniszczuk J, Beldi-Ferchiou A, Audureau E, et al. Circulating plasmablasts and high level of BAFF are hallmarks of minimal change nephrotic syndrome in adults[J/OL]. Nephrology, Dialysis, Transplantation: Official Publication of the European Dialysis and Transplant Association - European Renal Association, 2021, 36(4): 609-617. DOI: 10.1093/ndt/gfaa279.
[22]Thorley-Lawson D A. EBV Persistence--Introducing the Virus[J/OL]. Current Topics in Microbiology and Immunology, 2015, 390(Pt 1): 151-209. DOI: 10.1007/978-3-319-22822-8_8.
[23]Dossier C, Sellier-Leclerc A L, Rousseau A, et al. Prevalence of herpesviruses at onset of idiopathic nephrotic syndrome[J/OL]. Pediatric Nephrology (Berlin, Germany), 2014, 29(12): 2325-2331. DOI: 10.1007/s00467-014-2860-1.
[24]Chan E Y H, Sinha A, Yu E L M, et al. An international, multi-center study evaluated rituximab therapy in childhood steroid-resistant nephrotic syndrome[J/OL]. Kidney International, 2024, 106(6): 1146-1157. DOI: 10.1016/j.kint.2024.09.011.
[25]Liu J, Deng F, Wang X, et al. Early Rituximab as an Add-On Therapy in Children With the Initial Episode of Nephrotic Syndrome[J/OL]. Kidney International Reports, 2024, 9(5): 1220-1227. DOI: 10.1016/j.ekir.2024.02.1395.
[26]Zhang X, Jin Y, Liu F, et al. Rituximab as a first-line therapy in children with new-onset idiopathic nephrotic syndrome[J/OL]. Clinical Kidney Journal, 2025, 18(1): sfae348. DOI: 10.1093/ckj/sfae348.
[27]中华医学会肾脏病学分会专家组, Nephrology C S of. 利妥昔单抗在肾小球肾炎中应用的专家共识[J/OL]. 中华肾脏病杂志, 2022: 151-160. DOI: 10.3760/cma.j.cn441217-20210615-00023.
[28]Sellier-Leclerc A L, Baudouin V, Kwon T, et al. Rituximab in steroid-dependent idiopathic nephrotic syndrome in childhood--follow-up after CD19 recovery[J/OL]. Nephrology, Dialysis, Transplantation: Official Publication of the European Dialysis and Transplant Association - European Renal Association, 2012, 27(3): 1083-1089. DOI: 10.1093/ndt/gfr405.
[29]Furie R A, Aroca G, Cascino M D, et al. B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial[J/OL]. Annals of the Rheumatic Diseases, 2022, 81(1): 100-107. DOI: 10.1136/annrheumdis-2021-220920.
[30]Sun L L, Ellerman D, Mathieu M, et al. Anti-CD20/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies[J/OL]. Science Translational Medicine, 2015, 7(287): 287ra70. DOI: 10.1126/scitranslmed.aaa4802.
[31]Neelapu S S, Locke F L, Bartlett N L, et al. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma[J/OL]. The New England Journal of Medicine, 2017, 377(26): 2531-2544. DOI: 10.1056/NEJMoa1707447.
[32]Cappell K M, Kochenderfer J N. Long-term outcomes following CAR T cell therapy: what we know so far[J/OL]. Nature Reviews. Clinical Oncology, 2023, 20(6): 359-371. DOI: 10.1038/s41571-023-00754-1.
版权与开放获取声明
作为一本开放获取的学术期刊，所有文章均遵循 Creative Commons Attribution 4.0 International License (CC BY 4.0) 协议发布，允许用户在署名原作者的前提下自由共享与再利用内容。所有文章均可免费供读者和机构阅读、下载、引用与传播，EWA Publishing 不会通过期刊的出版发行向读者或机构收取任何费用。